Abstract:Background: Infantile spasms (IS) is an age-specific and severe epileptic encephalopathy that occurs in infancy and early childhood and is usually refractory to conventional antiepileptic drugs. Adrenocorticotropic hormone (ACTH) has been the treatment of choice for IS, but ACTH use has been associated with infection and hypertension. Magnesium ion is an N-methyl-D-aspartic acid (NMDA) noncompetitive antagonist that might inhibit NMDA activity and has antiepileptic and neuroprotective effects.Objective: This study compared the efficacy and tolerability of ACTH + magnesium sulfate (MgSO4) versus ACTH monotherapy for the treatment of IS.Methods: This 24-week, randomized, open-label follow-up study enrolled male and female infants with IS. Patients were randomly assigned to receive ACTH 25 U/d + MgSO4 0.25 g/kg/d, or ACTH 25 U/d only (control), intravenously for 3 weeks. Efficacy was assessed over a period of 24 weeks based on seizure frequency, EEG, and Gesell testing of psychomotor skills (subscales: language, motor, adaptive, and personal-social skills; measured using a developmental quotient [DQ]). Tolerability was assessed by monitoring for adverse events using laboratory analysis and clinical evaluation.Results: Thirty-eight infants were enrolled (23 male, 15 female; median age, 9.2 months; 19 patients per group). At 12 weeks, 14 patients (73.7%) who received ACTH + MgSO4 and 9 patients (47.4%) in the control group were seizure free. At 24 weeks, seizure-free rates were 12 (63.2%) in the ACTH + MgSO4 group and 10 (52.6%) in the control group. On EEG, 9 patients (47.4%) in the ACTH + MgSO4 group achieved complete recovery (normalized EEG), 5 (26.3%) attained partial improvement (multifocal spike wave), and 5 (26.3%) had no improvement (hypsarrhythmia or modified hypsarrhythmia). At 4 weeks, in the control group, 5 patients (26.3%) achieved complete recovery, 6(31.6%) achieved partial improvement, and 8(42.1%) had no improvement. Of the 12 patients who were seizure free at 24 weeks in the ACTH + MgSO4 group, 11(91.7%) had complete recovery (normalized EEG); this rate was 7 of 10 (70.0%) in the control group. In the ACTH + MgSO4 group, the change from baseline to 24 weeks in mean (SD) personal-social DQ was significant (from 48.6 [6.4] to 65.2 [7.1], respectively; P < 0.05). In the control group, the difference before and after treatment was nonsignificant (47.7 [6.0] vs 49.9 [4.4]). None of the other Gesell test findings were significant versus baseline. The most common AEs included upper respiratory tract infection and pyrexia (both, 3 [15.8%] per group); diarrhea (2 [10.5%] per group); and hypertension, insomnia, and irritability (all, 0 in the ACTH + MgSO4 group and 2 [10.5%] in the control group). None of the between-group differences in the prevalences of AEs were significant between the 2 groups.Conclusions: In this study in infants with IS, the proportions of patients who were seizure free from 4 to 24 weeks were significantly greater in the ACTH + MgSO4 group compared with the ACTH monotherapy group. Personal-social neurodevelopment was significantly improved from baseline in the group that received combination treatment. Both treatments were generally well tolerated. International Standard Randomized Controlled Trial no. ISRCTN 78654111. (Clin Ther 2010; 32:692-700) (C) 2010 Excerpta Medica Inc.

Adrenocorticotropic Hormone Combined with Magnesium Sulfate Therapy for Infantile Epileptic Spasms Syndrome: a Real-World Study

Interictal EEG Based Prediction of ACTH Efficacy in Infantile Epileptic Spasms

Three-week Combination Treatment with ACTH + Magnesium Sulfate Versus ACTH Monotherapy for Infantile Spasms: a 24-Week, Randomized, Open-Label, Follow-Up Study in China.

An Open-Label Clinical Study on the Efficacy and Tolerability of Magnesium Sulfate Combined with Adrenocorticotropic Hormone Treatment on Infantile Spasm

Response to Magnesium Sulfate and Adrenocorticotropic Hormone Combination Therapy for Infantile Spasms with Failed First-Line Treatments

Electroencephalography Changes in Infantile Spasm During Magnesium Sulfate Adjuvant Treatment:A Randomized Study with Control Therapy

[Factors Influencing the Efficacy of Initial Adrenocorticotropic Hormone Therapy for Infantile Epileptic Spasms Syndrome].

A case-control study about the preventive effect of magnesium sulfate on hypertention caused by ACTH in the treatment of infantile spasms

Effectiveness and Safety of Different Once-Daily Doses of Adrenocorticotropic Hormone for Infantile Spasms

Infantile Epileptic Spasms Syndrome Complicated by Leigh Syndrome and Leigh-Like Syndrome: A Retrospective, Nationwide, Multicenter Case Series

Effect of Electroencephalogram Changes in Infantile Spasms Treated with Adrenocorticotropic Hormone

Hormonal Therapy for Infantile Spasms: A Systematic Review and Meta-Analysis

The Efficacy and Safety of Different Doses of ACTH Therapy for Infantile Spasms:A Meta-Analysis

Safety and Effectiveness of Oral Methylprednisolone Therapy in Comparison With Intramuscular Adrenocorticotropic Hormone and Oral Prednisolone in Children With Infantile Spasms

Efficacy and safety of corticosteroids and ACTH in epileptic syndromes beyond Infantile Epileptic Spasms Syndrome (IESS): A systematic review and meta‐analysis

[Effect of Prednisolone and Adrenocorticotropic Hormone in the Treatment of Infantile Spasms: a Meta Analysis].

Clinical effects of low-dose ACTH combined with valproate on infantile spasms

Abnormalities in Clostridioides and related metabolites before ACTH treatment may be associated with its efficacy in patients with infantile epileptic spasm syndrome

Retrospective study of different doses of ACTH therapy for infantile spasms

Adrenocorticotropic hormone therapy alters Q-albumin ratios in patients with infantile epileptic spasms syndrome of unknown etiology

Safety and efficacy of melatonin supplementation as an add‐on treatment for infantile epileptic spasms syndrome: A randomized, placebo‐controlled, double‐blind trial